Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome
NCT: NCT03325959 · COMPLETED
Brief Summary
The investigators have previously studied the efficacy of hyperbaric oxygen therapy (HBOT) as a treatment for Fibromyalgia syndrome (FMS) in a prospective, active control, crossover clinical trial. The results demonstrated significant amelioration of all FMS symptoms, with significant improvement in life quality; furthermore, the investigators were able to demonstrate significant neuroplasticity on SPECT imaging, with a decrease of the hyperactivity in posterior regions and elevation of the reduced activity in frontal areas. In the proposed study, the investigators intend to both repeat and expand our previous findings, treating FMS patients with HBOT while performing an extensive of evaluation both before and after treatment. In the current study, the investigators plan to compare HBOT to current standard of care of FMS (pharmacological and non - pharmacological).
Frequently Asked Questions
What is Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome?
Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome is a clinical trial registered under NCT03325959. Current status: COMPLETED.
What is the status of NCT03325959?
The current status of NCT03325959 (Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome) is: COMPLETED.
When did Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome start?
Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome started on 2017-03-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.